The First Oral Hormone Therapy for Advanced Prostate Cancer Receives FDA Approval

For patients with advanced prostate cancer, the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, marketed as Orgovyx, was approved on 18 December 2020 by the US Food and Drug Administration (FDA).
This approval is the first for an oral medicine in this class of hormonal treatment. It may reduce how often patients need to visit a healthcare facility. During the COVID-19 Pandemic, many patients are understandably reluctant to visit healthcare facilities; the potential of new medicines to reduce clinic visits may be particularly helpful in allowing patients with cancer to stay at home.
2018 World Cancer Statistics report that 1.28 million new prostate cancer cases are diagnosed each year.
How does relugolix work?
The main treatment for advanced prostate cancer is androgen deprivation therapy, which uses medicines to lower male hormone levels that help prostate cancer grow. Previous FDA-approved treatments of this type are injected or placed under the skin as small implants. Relugolix (Orgovyx) binds to gonadotropin-releasing hormone (GnRH) receptors and prevents the pituitary gland from making luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is an oral treatment that works by reducing the amount of testosterone the testicles can produce. It is a hormone therapy in the GnRH receptor antagonist class.
The HERO study
The safety and efficacy of relugolix were evaluated in men with recurrent prostate cancer after radiotherapy or surgery, or newly diagnosed metastatic castration-sensitive advanced prostate cancer requiring at least one year of androgen deprivation therapy, in HERO, a randomized, open-label study. A total of 934 patients were randomly assigned in a 2:1 ratio to one of 2 arms: oral relugolix with a 360 mg loading dose on the first day followed by daily oral doses of 120 mg, or subcutaneous injections of 22.5 mg leuprolide acetate, another hormone-targeting medicine, every 3 months for 48 weeks. The aim was to determine whether relugolix achieved sufficiently low testosterone levels (castration levels) from treatment day 29 until the end of treatment (testosterone <50 ng / dL).
The castration rate in 622 patients receiving relugolix was 96.7%.
Side effects
The most common side effects of relugolix include hot flushes, increased glucose, increased triglycerides, musculoskeletal pain, decreased haemoglobin, fatigue, constipation, diarrhoea and increased levels of certain liver enzymes. Androgen deprivation therapies such as relugolix may affect the heart's electrical properties or cause electrolyte abnormalities, so healthcare providers should consider periodic monitoring of electrocardiograms and electrolytes. Based on animal findings and its mechanism of action, relugolix may cause fetal harm and pregnancy loss if given to a pregnant woman; men with female partners of reproductive potential are advised to use effective contraception during treatment and for two weeks after the last relugolix dose.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.